- Our Team
Dr. Huafeng Wei is a Professor of Anesthesiology and Critical Care at the Perelman School of Medicine at Penn and serves as an attending anesthesiologist at the Hospital of the University of Pennsylvania. Dr. Wei received his medical degree at Tongji Medical University in Wuhan, China and subsequently completed his PhD in Pharmacology and Toxicology at George Washington University. As President of the International Airway Management Society, his work focuses on the role of calcium dysregulation in Alzheimer's disease and innovations in clinical practices for airway management. Dr. Wei is also an internationally recognized practitioner of tai chi (a Chinese martial art).
Dr. Grace Liang is the lab manager and staff scientist for the Wei Lab. Her research centers on the implications of calcium homeostasis on AD pathogenesis and propagation of disease biomarkers in induced pluripotent stem cell (iPSC) models.
Robert is a staff researcher at the Wei Lab. He is particularly interested in the behavioral markers of AD progression in animal disease models, including differences in spatial reference memory, working memory, and locomotor ability.
Nick (C'23) is an undergraduate researcher with the Wei Lab and a Neurobiology major in the School of Arts and Sciences. He is interested in the mechanisms and effects of intranasally administered therapeutic agents in animal models of Alzheimer's disease, including their effects on neurogenesis, synaptogenesis, and tau pathology.
Ipsita (C'24) is an undergraduate researcher with the Wei Lab and currently studies Neuroscience in the School of Arts and Sciences. Her research focuses upon the interactions between pharmacological treatments and calcium regulatory pathways in induced cell disease models.
Sam (C'24) is an undergraduate researcher with the Wei Lab and a student in the Life Sciences and Management Program at Penn. His research interests include testing of therapeutic agents on AD pathologies in induced cell models and mutational interactions between treatment drugs and the S2 subunit of the SARS-Cov-2 virus.